The positive revenue forecast could support investor confidence in Bioventus's growth trajectory, potentially offsetting concerns over the lower-than-expected adjusted EPS forecast. The mixed financial outlook suggests a neutral short-term impact on BVS stock as investors weigh the higher sales against the lower profitability outlook.